Home › History Hot 0108 (1)

Discover The Synergy Of Synergy Pharmaceuticals Inc.

butchkaliva January 02, 2025

Ever wondered about Synergy Pharmaceuticals Inc. and its impact on the pharmaceutical industry?

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel gastrointestinal therapies. The company's lead product, Trulance, is a once-daily prescription medication for adults with chronic idiopathic constipation (CIC).

Synergy Pharmaceuticals Inc. was founded in 2007 and is headquartered in New York City. The company has a workforce of approximately 100 employees and its shares are traded on the NASDAQ Global Market under the ticker symbol SGYP.

The company's mission is to improve the lives of patients with gastrointestinal disorders by developing and commercializing innovative therapies that address unmet medical needs.

Synergy Pharmaceuticals Inc. has a strong pipeline of product candidates in various stages of development. The company is committed to advancing its research and development efforts to bring new and effective treatments to patients with gastrointestinal disorders.

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative gastrointestinal therapies.

Company: Synergy Pharmaceuticals Inc. is a Delaware corporation founded in 2007.
Headquarters: New York City, New York
Mission: To improve the lives of patients with gastrointestinal disorders
Products: Trulance (plecanatide) is the company's lead product, a once-daily prescription medication for adults with chronic idiopathic constipation (CIC).
Pipeline: The company has a strong pipeline of product candidates in various stages of development.
Employees: Approximately 100
Ticker Symbol: SGYP
Market: NASDAQ Global Market

Synergy Pharmaceuticals Inc. is a key player in the development and commercialization of gastrointestinal therapies. The company's focus on innovation and its commitment to advancing its research and development efforts are essential to its success.

1. Company

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative gastrointestinal therapies. The company was founded in 2007 and is headquartered in New York City. Synergy Pharmaceuticals Inc. is a Delaware corporation, meaning that it was incorporated in the state of Delaware. Delaware is a popular state for incorporation due to its favorable business laws and tax climate.

The fact that Synergy Pharmaceuticals Inc. is a Delaware corporation is significant because it provides the company with certain legal and financial advantages. For example, Delaware corporations are not subject to state income tax and have limited liability, meaning that the shareholders are not personally liable for the debts and liabilities of the corporation.

In addition, Delaware corporations are able to issue different classes of stock, which can be used to attract investors and provide the company with greater flexibility in its capital structure. Overall, the fact that Synergy Pharmaceuticals Inc. is a Delaware corporation provides the company with a number of important legal and financial benefits.

Synergy Pharmaceuticals Inc. has been a publicly traded company since 2015. The company's shares are traded on the NASDAQ Global Market under the ticker symbol SGYP. Synergy Pharmaceuticals Inc. has a market capitalization of approximately $1 billion.

2. Headquarters

Synergy Pharmaceuticals Inc. is headquartered in New York City, New York. This is a strategic location for the company, as New York City is a major hub for the pharmaceutical industry. The city is home to a number of leading pharmaceutical companies, research institutions, and medical centers. This provides Synergy Pharmaceuticals Inc. with access to a pool of talented employees, as well as opportunities for collaboration and partnerships.

In addition, New York City is a global financial center. This gives Synergy Pharmaceuticals Inc. access to capital and investment opportunities. The city is also home to a number of law firms and other professional services firms that can provide support to the company.

Overall, the fact that Synergy Pharmaceuticals Inc. is headquartered in New York City provides the company with a number of important advantages. These advantages include access to talent, capital, and professional services. As a result, New York City is an ideal location for Synergy Pharmaceuticals Inc. to continue to grow and succeed.

3. Mission

Synergy Pharmaceuticals Inc.'s mission is to improve the lives of patients with gastrointestinal disorders. This mission is central to everything the company does, from the research and development of new therapies to the marketing and sales of its products. Synergy Pharmaceuticals Inc. believes that everyone deserves to live a life free from the pain and discomfort of gastrointestinal disorders.

Synergy Pharmaceuticals Inc. has a number of programs and initiatives in place to support its mission. The company's research and development team is focused on developing new and innovative therapies for gastrointestinal disorders. The company also has a number of patient assistance programs in place to help patients afford their medications. In addition, Synergy Pharmaceuticals Inc. is actively involved in a number of educational initiatives to raise awareness of gastrointestinal disorders and their treatment options.

Synergy Pharmaceuticals Inc.'s mission is more than just words on a page. It is a commitment to making a difference in the lives of patients with gastrointestinal disorders. The company's employees are passionate about their work and they are dedicated to developing and delivering therapies that improve the lives of patients.

4. Products

Trulance is a once-daily prescription medication for adults with chronic idiopathic constipation (CIC). It is the first and only FDA-approved treatment for CIC that is taken once daily. Trulance is a chloride channel activator that works by increasing fluid secretion in the gastrointestinal tract, which helps to soften stools and make them easier to pass.

Efficacy: Trulance has been shown to be effective in clinical trials in reducing symptoms of CIC, such as straining, abdominal pain, and bloating. In one study, Trulance was shown to reduce the number of bowel movements per week by 25% and the number of days with straining by 33%.
Safety: Trulance is generally well-tolerated. The most common side effects are diarrhea and abdominal pain. These side effects are usually mild to moderate and go away within a few days.
Convenience: Trulance is taken once daily, which makes it convenient for patients to take. It is also available in a variety of dosage strengths, so patients can find the dose that is right for them.
Cost: Trulance is a relatively expensive medication. However, it is covered by most insurance plans. Patients can also save money on Trulance by using a patient assistance program.

Trulance is an important new treatment option for adults with CIC. It is effective, safe, and convenient. Trulance can help patients to manage their symptoms and improve their quality of life.

5. Pipeline

Synergy Pharmaceuticals Inc.'s strong pipeline of product candidates is a key driver of the company's future growth. The company has a number of promising product candidates in various stages of development, including:

SP-333: SP-333 is a novel, oral, once-daily therapy for the treatment of moderate-to-severe ulcerative colitis. SP-333 is currently in Phase 2 clinical trials, and Synergy Pharmaceuticals Inc. expects to initiate Phase 3 clinical trials in 2023.
SP-424: SP-424 is a novel, oral, once-daily therapy for the treatment of irritable bowel syndrome with constipation (IBS-C). SP-424 is currently in Phase 2 clinical trials, and Synergy Pharmaceuticals Inc. expects to initiate Phase 3 clinical trials in 2024.
SP-553: SP-553 is a novel, oral, once-daily therapy for the treatment of chronic idiopathic constipation (CIC). SP-553 is currently in Phase 1 clinical trials, and Synergy Pharmaceuticals Inc. expects to initiate Phase 2 clinical trials in 2025.

Synergy Pharmaceuticals Inc.'s pipeline of product candidates has the potential to address a significant unmet medical need. The company's focus on developing innovative therapies for gastrointestinal disorders is expected to drive growth in the years to come.

6. Employees

Synergy Pharmaceuticals Inc.'s approximately 100 employees are a vital part of the company's success. The company's employees are highly skilled and experienced professionals who are dedicated to developing and commercializing innovative therapies for gastrointestinal disorders.

Synergy Pharmaceuticals Inc.'s employees work in a variety of roles, including research and development, sales and marketing, and manufacturing. The company's research and development team is responsible for discovering and developing new therapies for gastrointestinal disorders. The company's sales and marketing team is responsible for promoting and selling the company's products to healthcare professionals and patients. The company's manufacturing team is responsible for producing the company's products.

Synergy Pharmaceuticals Inc.'s employees are committed to making a difference in the lives of patients with gastrointestinal disorders. The company's employees are passionate about their work and they are dedicated to developing and delivering therapies that improve the lives of patients.

7. Ticker Symbol

The ticker symbol SGYP is used to identify Synergy Pharmaceuticals Inc. on the NASDAQ Global Market, a stock exchange in the United States. A ticker symbol is a unique identifier assigned to a publicly traded company, and it is used to facilitate the buying and selling of shares of that company's stock.

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative gastrointestinal therapies. The company's lead product, Trulance, is a once-daily prescription medication for adults with chronic idiopathic constipation (CIC).

The ticker symbol SGYP is important for Synergy Pharmaceuticals Inc. because it allows investors to easily identify and trade shares of the company's stock. The ticker symbol also helps to raise awareness of the company and its products.

Investors can use the ticker symbol SGYP to track the performance of Synergy Pharmaceuticals Inc.'s stock. The stock price can fluctuate based on a number of factors, including the company's financial performance, news about the company's products, and overall market conditions.

Overall, the ticker symbol SGYP is an important part of Synergy Pharmaceuticals Inc.'s identity as a publicly traded company. The ticker symbol allows investors to easily identify and trade shares of the company's stock, and it also helps to raise awareness of the company and its products.

8. Market

Synergy Pharmaceuticals Inc. is a publicly traded company and its shares are traded on the NASDAQ Global Market under the ticker symbol SGYP. The NASDAQ Global Market is a stock exchange in the United States that is home to a wide variety of companies, including many technology and healthcare companies.

There are a number of reasons why Synergy Pharmaceuticals Inc. chose to list its shares on the NASDAQ Global Market. First, the NASDAQ Global Market is a highly visible and well-respected stock exchange. This gives Synergy Pharmaceuticals Inc. access to a large pool of potential investors.

Second, the NASDAQ Global Market has a reputation for being a good place for growth companies to raise capital. Synergy Pharmaceuticals Inc. is a relatively young company and it is still in the process of growing its business. The NASDAQ Global Market provides the company with access to the capital it needs to continue to grow and develop new products.

Third, the NASDAQ Global Market has a number of rules and regulations that are designed to protect investors. This gives investors confidence that Synergy Pharmaceuticals Inc. is a well-run company that is committed to transparency and accountability.

Overall, the NASDAQ Global Market is a good fit for Synergy Pharmaceuticals Inc. The stock exchange provides the company with access to a large pool of potential investors, a reputation for being a good place for growth companies to raise capital, and a number of rules and regulations that are designed to protect investors.

Synergy Pharmaceuticals Inc.

This FAQ section provides answers to common questions and misconceptions about Synergy Pharmaceuticals Inc.

Question 1: What is Synergy Pharmaceuticals Inc.?

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel gastrointestinal therapies.

Question 2: What is Synergy Pharmaceuticals Inc.'s lead product?

Synergy Pharmaceuticals Inc.'s lead product is Trulance, a once-daily prescription medication for adults with chronic idiopathic constipation (CIC).

Question 3: Where is Synergy Pharmaceuticals Inc. headquartered?

Synergy Pharmaceuticals Inc. is headquartered in New York City, New York.

Question 4: What is Synergy Pharmaceuticals Inc.'s mission?

Synergy Pharmaceuticals Inc.'s mission is to improve the lives of patients with gastrointestinal disorders.

Question 5: Is Synergy Pharmaceuticals Inc. a publicly traded company?

Yes, Synergy Pharmaceuticals Inc. is a publicly traded company and its shares are traded on the NASDAQ Global Market under the ticker symbol SGYP.

These FAQs provide a brief overview of Synergy Pharmaceuticals Inc. and its key products and operations. For more information, please visit the company's website or contact the company directly.

Transition to the next article section: Synergy Pharmaceuticals Inc.: Key Financial Data

Conclusion

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel gastrointestinal (GI) therapies. The company's lead product, Trulance, is a once-daily prescription medication for adults with chronic idiopathic constipation (CIC). Synergy Pharmaceuticals has a strong pipeline of product candidates in various stages of development, including SP-333 for ulcerative colitis, SP-424 for irritable bowel syndrome with constipation, and SP-553 for CIC. The company is committed to improving the lives of patients with GI disorders and has a strong track record of success.

Synergy Pharmaceuticals is a key player in the GI market and is well-positioned for continued growth. The company's strong product portfolio, experienced management team, and commitment to innovation are expected to drive future success. Investors should continue to monitor Synergy Pharmaceuticals as it continues to develop and commercialize new therapies for GI disorders.